Barclays’s Enveric Biosciences ENVB Stock Holding History

Barclays’s Portfolio ENVB Stock Details ENVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3	Closed	-$42	–	5347
2025 Q1	$42	Buy	+3	New	+$104	﹤0.01%	5153
2019 Q4	–	Hold	0	–	-$48K	–	6455
2019 Q3	–	Hold	0	–	–	–	5923
2019 Q2	–	Hold	0	–	–	–	6322

Other funds holding ENVB

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Barclays's ENVB Position: Q2 2025 in Review

Barclays sold out of Enveric Biosciences (ENVB) in Q2 2025, closing a stake of 3 shares — an estimated $42 sold.

Barclays first reported a position in ENVB in Q1 2025 and held it in 1 quarter. The position peaked at $42 in Q1 2025. 10 funds tracked by Wall St. Rank hold ENVB as of Q2 2025.

Barclays reported no remaining Enveric Biosciences position as of Q2 2025 after selling out during the quarter.
Barclays sold 3 Enveric Biosciences shares in Q2 2025, an estimated $42.
Barclays first reported a position in Enveric Biosciences in Q1 2025 and held it in 1 quarter.
Barclays's Enveric Biosciences position peaked at $42 in Q1 2025.
10 funds tracked by Wall St. Rank held Enveric Biosciences as of Q2 2025.

Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.